-+ 0.00%
-+ 0.00%
-+ 0.00%

LUNDBECK ANNOUNCES HEADLINE RESULTS FROM PHASE IV THRIVE TRIAL EVALUATING VYEPTI® (EPTINEZUMAB) FOLLOWING INADEQUATE RESPONSE TO PRIOR CGRP-TARGETING PREVENTIVE THERAPY

Reuters·10/01/2026 06:18:01

Please log in to view news